Enveda propune o nouă direcție în lupta cu obezitatea

Enveda is testing ENV-308, an experimental oral drug inspired by Lac-Phe, linked to physical exertion response. Phase I study involved 88 healthy adults, focusing on safety rather than weight loss effects. No serious adverse reactions were reported, and results showed a decrease in circulating leptin, especially in participants with initially higher levels. Future studies will assess the drug's impact on weight and body composition, potentially in combination with GLP-1 therapies.